{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:48:15Z","timestamp":1793645295912,"version":"4.5.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Hematopoietic stem cell transplant (HCT) is used for many pediatric malignant and non-malignant diseases. However, these patients are at a high risk for emergencies post-transplant, related to prior comorbidities and treatments for the underlying disease, high dose chemotherapy regimen related toxicities, prolonged myelosuppression, and opportunistic infections due to their immunocompromised state. Emergencies can be during preparative regimen and hematopoietic progenitor cell (HPC) infusion, acute post-transplant (pre-engraftment) and late during post engraftment. Infectious complications are the most common cause of morbidity and mortality in the peri-transplant period. Sinusoidal obstructive syndrome is another life-threatening emergency seen in children undergoing HCT, especially in infants. Timely recognition and administration of defibrotide with\/without steroids is key to the management of this complication. Another complication seen is transplant associated thrombotic microangiopathy. It can cause multiorgan failure if left untreated and demands urgent identification and management with complement blockade agents such as eculizumab. Cytokine release syndrome and cytokine storm is an important life-threatening complication seen after cellular therapy, and needs emergent intervention with ICU supportive care and tocilizumab. Other complications in acute period include but are not limited to: seizures from busulfan or other chemotherapy agents, PRES (posterior reversible encephalopathy syndrome), diffuse alveolar hemorrhage, idiopathic pulmonary syndrome and allergic reaction to infusion of stem cells. Acute graft versus host disease (GvHD) is a major toxicity of allogeneic HCT, especially with reduced intensity conditioning, that can affect the skin, liver, upper and lower gastrointestinal tract. There has been major development in new biomarkers for early identification and grading of GvHD, which enables application of treatment modalities such as post-transplant cyclophosphamide and JAK\/STAT inhibitors to prevent and treat GvHD. Myelosuppression secondary to the chemotherapy increases risk for engraftment syndrome as well as coagulopathies, thus increasing the risk for clotting and bleeding in the pediatric population. The purpose of this article is to review recent literature in these complications seen with pediatric hematopoietic cell transplant (HCT) and cellular therapies and provide a comprehensive summary of the major emergencies seen with HCT<\/jats:p>","DOI":"10.3389\/fped.2023.1075644","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:02:54Z","timestamp":1675760574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Medical emergencies in pediatric blood &amp; marrow transplant and cellular therapies"],"prefix":"10.3389","volume":"11","author":[{"given":"Nikki","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Rotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2352-3026(15)00028-9","article-title":"One million hematopoietic stem cell transplants: a retrospective observtional study 2015; 2(3):e91\u2013100","volume":"2","author":"Gratwohl","year":"2015","journal-title":"Lancet Hematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1056\/NEJMp078166","article-title":"Hematopoietic-cell transplantation at 50","volume":"357","author":"Appelbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.bbmt.2008.06.008","article-title":"Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants","volume":"14","author":"Majhail","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2010-08-303263","article-title":"Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients","volume":"117","author":"Smith","year":"2011","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/21505594.2016.1208866","article-title":"Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection","volume":"16","author":"Mehta","year":"2016","journal-title":"Virulence"},{"key":"B9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/CCM.0000000000000714","article-title":"Severe sepsis in hematopoietic stem cell transplant recipients*","volume":"43","author":"Kumar","year":"2015","journal-title":"Crit Care Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s00277-016-2654-6","article-title":"The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)","volume":"95","author":"Ishida","year":"2016","journal-title":"Ann Hematol"},{"key":"B11","year":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"e13498","DOI":"10.1111\/tid.13498","article-title":"Infectious complications after allogeneic hematopoietic stem cell transplantation in children in a bone marrow transplant unit in Colombia","volume":"23","author":"Bravo","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ajic.2020.07.020","article-title":"Impact of hospital acquired infections on post-transplant one year mortality in pediatric bone marrow transplant patients","volume":"49","author":"Hanisch","year":"2021","journal-title":"Am J Infect Control"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1399-3062.2005.00088.x","article-title":"Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients","volume":"7","author":"Almyroudis","year":"2005","journal-title":"Transpl Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1046\/j.1365-2141.2002.03457.x","article-title":"Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey: invasive Pneumococcal Infections Post-SCT","volume":"117","author":"Engelhard","year":"2002","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/bmt.2015.316","article-title":"The incidence, mortality and timing of Pneumocystis jiroveci pneumonia after hematopoietic cell transplantation: a CIBMTR analysis","volume":"51","author":"Williams","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1080\/14656566.2021.1915989","article-title":"Pneumocystis jirovecii: a review with a focus on prevention and treatment","volume":"22","author":"Weyant","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13613-020-00649-9","article-title":"Adjunctive corticosteroids may be associated with better outcome for non-HIV Pneumocystis pneumonia with respiratory failure: a systemic review and meta-analysis of observational studies","volume":"10","author":"Ding","year":"2020","journal-title":"Ann Intensive Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"CMV viral load and mortality after hematopoietic cell transplantation: a cohort study in the era of preemptive therapy","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","article-title":"Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence","volume":"221","author":"Haidar","year":"2020","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-118-3-199302010-00003","article-title":"Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant","volume":"118","author":"Goodrich","year":"1993","journal-title":"Ann Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.bbmt.2017.07.025","article-title":"Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring","volume":"23","author":"Yong","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2049936121991377","DOI":"10.1177\/2049936121991377","article-title":"Management of BK virus-associated haemorrhagic cystitis in allogeneic stem cell transplant recipients","volume":"8","author":"Jandial","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.bbmt.2018.04.009","article-title":"Efficacy of cidofovir in treatment of BK virus-induced hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients","volume":"24","author":"Coomes","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, epstein-barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.3390\/jcm11164827","article-title":"Adenovirus infection in pediatric hematopoietic cell transplantation: a challenge still open for survival","volume":"11","author":"Cesaro","year":"2022","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/sj.bmt.1704069","article-title":"Incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients","volume":"32","author":"Barker","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3324\/%25x","article-title":"A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation","volume":"90","author":"Cesaro","year":"2005","journal-title":"Haematologica"},{"key":"B32","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation","volume":"53","author":"Corbacioglu","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","article-title":"Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome","volume":"16","author":"Coppell","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"B34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.bmt.1705835","article-title":"Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation","volume":"40","author":"Cheuk","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.13215","article-title":"How I manage sinusoidal obstruction syndrome after haematopoietic\u00a0cell transplantation","volume":"168","author":"Carreras","year":"2015","journal-title":"Br J Haematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbmt.2006.09.012","article-title":"Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation","volume":"13","author":"Tay","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.bmt.1701782","article-title":"Opportunistic CNS infection after bone marrow transplantation","volume":"23","author":"Maschke","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.bbmt.2017.05.033","article-title":"Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies","volume":"23","author":"Gaziev","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3389\/fneur.2020.00463","article-title":"Posterior Reversible Encephalopathy Syndrome (PRES): pathophysiology and neuro-imaging","volume":"11","author":"Anderson","year":"2020","journal-title":"Front Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fneur.2020.00194","article-title":"Clinical and MRI features of posterior reversible encephalopathy syndrome with atypical regions: a descriptive study with a large sample size","volume":"11","author":"Li","year":"2020","journal-title":"Front Neurol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/1941874412455338","article-title":"Neurological complications of transplantation: part I: hematopoietic cell transplantation","volume":"3","author":"Pruitt","year":"2013","journal-title":"Neurohospitalist"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","article-title":"A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant","volume":"5","author":"Dandoy","year":"2021","journal-title":"Blood Adv"},{"key":"B47","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/bmt.2010.182","article-title":"Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT","volume":"46","author":"Laskin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"B48","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"B49","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.bbmt.2015.06.016","article-title":"Histologic features of intestinal thrombotic microangiopathy in pediatric and young adult patients after hematopoietic stem cell transplantation","volume":"21","author":"El-Bietar","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41409-020-0880-y","article-title":"Histologic features of hematopoietic stem cell transplant-associated thrombotic microangiopathy are best percepted in deep skin biopsies and renal biopsies, while showing a significant overlap with changes related to severe acute graft-versus-host disease in gastrointestinal biopsies","volume":"55","author":"Ehmann","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.blre.2014.11.001","article-title":"A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury","volume":"29","author":"Jodele","year":"2015","journal-title":"Blood Rev"},{"key":"B53","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/bmt.2014.40","article-title":"Pericardial effusion in pediatric SCT recipients with thrombotic microangiopathy","volume":"49","author":"Lerner","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41467-021-21078-7","article-title":"Engineering advanced logic and distributed computing in human CAR immune cells","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2015-10-612747","article-title":"How I treat acute graft-versus-host disease of the gastrointestinal\u00a0tract and the liver","volume":"127","author":"McDonald","year":"2016","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1182\/blood-2003-05-1597","article-title":"Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation","volume":"102","author":"Fukuda","year":"2003","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.3389\/fonc.2020.01757","article-title":"Diffuse alveolar hemorrhage after pediatric hematopoietic stem cell transplantation","volume":"10","author":"Fan","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1075644\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T09:02:58Z","timestamp":1675760578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1075644\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":66,"alternative-id":["10.3389\/fped.2023.1075644"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1075644","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"1075644"}}